Male hypogonadism is documented low testosterone — confirmed by morning serum testosterone < 8.0 nmol/L on at least two occasions, with characteristic symptoms (fatigue, low libido, erectile dysfunction, depressed mood, loss of muscle mass, anaemia, bone-density loss). Testosterone replacement therapy (TRT) restores physiological levels and improves these outcomes. Fertility-preserving alternatives (clomiphene / enclomiphene / hCG) avoid the testicular shutdown and infertility caused by exogenous testosterone — relevant for younger men still wanting children. The MedsBase Hypogonadism catalogue carries the topical TRT options, supplied by WHO-GMP πιστοποιημένους κατασκευαστές.
Topical testosterone gel. Topical 1% testosterone gel applied daily to clean dry skin (shoulders, upper arms, abdomen) — typically 50–100 mg gel daily depending on baseline level and target serum testosterone. Stable serum levels are achieved at 7–14 days; trough level checked 2–4 hours after application or 24 hours later (depending on protocol) to confirm adequate replacement. Stocked as Androtas Gel 75 g και Androtas Gel 5 g.
Application and contact precautions. Apply once daily, allow to dry 5–10 minutes, wash hands thoroughly. Cover the application site to avoid skin-to-skin transfer to women or children — inadvertent transfer to women causes virilisation; transfer to children causes early puberty. Avoid swimming or showering for 4–6 hours after application.
Fertility-preserving alternatives — see related categories. Younger men still wanting children should consider hCG (HUCOG, Puretrig, Eutrig HP — see our Συμπληρώματα Γονιμότητας για Άνδρες category) or clomiphene / enclomiphene (Clomiford, Clomisign, Enclomisign) instead of TRT — these stimulate endogenous testosterone production without shutting down testicular function and spermatogenesis.
Σημαντικό. TRT is appropriate only for documented hypogonadism with confirmed low testosterone and characteristic symptoms — not for normal-range testosterone with non-specific symptoms or for performance enhancement. Baseline assessment before starting: serum testosterone (morning, fasting, ideally repeated on a separate day), LH/FSH (to distinguish primary from secondary hypogonadism), prolactin (rules out prolactinoma), PSA (baseline), haematocrit (TRT raises Hct — risk of polycythaemia), DEXA scan in selected cases. Monitoring: testosterone level + Hct + PSA at 3 and 6 months then annually. Contraindications: prostate cancer (active or treated within 5 years), male breast cancer, severe untreated sleep apnoea, uncontrolled heart failure, polycythaemia (Hct > 54%), planning fatherhood (use hCG / clomiphene instead). Cardiovascular safety signals from older studies were reassuring on more recent meta-analysis — but discuss risks with your endocrinologist.
All MedsBase Hypogonadism products ship from WHO-GMP πιστοποιημένους κατασκευαστές με διακριτική συσκευασία και καλύπτονται από την Πολιτική Εγγύησης Επαναποστολής.